Study on Predicting Response to Standard First-Line Treatment in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Using ctDNA Combined With PET

Sponsor
Fudan University
Study ID
NCT07070648
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • POLA-R-CHP — DRUG
    Pola-R-CHP treatment for 6 cycles (IPI score 2-5)

Study Details

This is a prospective, multicenter, multi-cohort study of ctDNA combined with PET for predicting the efficacy of standard first-line therapy for patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL).

Key Dates

First listed
Jul 17, 2025
Start date
May 9, 2025
Status verified
Jul 2025
Primary completion
Dec 30, 2026
Completion
Dec 30, 2027

Study Design

Enrollment
300 participants (estimated)

Arms

  • Arm: Pola-R-CHP treatment group (IPI score 2-5)
    Pola-R-CHP treatment group (IPI score 2-5)

Primary Outcome Measure

Correlation between combined PET/CT and ctDNA assessments after 2 cycles of R-CHOP or Pola-R-CHP therapy and progression-free survival (PFS) [ Time Frame: Baseline, Day 20 of Cycle 2, and 6 weeks after Cycle 6 completion（each cycle is 21 days） ]

Central Contacts

Related Studies